ReviewCroatian medical journal2021
Non-alcoholic fatty liver disease - a procoagulant condition?
Review in Croatian medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review.International journal of molecular sciences · 2025Pooled it
- Hemostatic dysfunction and thrombotic risk in metabolic dysfunction-associated steatotic liver disease.Journal of thrombosis and thrombolysis · 2026Review
- When Atrial Fibrillation Meets Alcoholic Liver Cirrhosis: Can Direct Oral Anticoagulants Bridge the Therapeutic Gap?Biomedicines · 2026Review
- Platelet-mediated progression of fatty liver disease in metabolic dysfunction-associated steatohepatitis: a pathophysiological review.Frontiers in medicine · 2026Review
- Translational framework linking perfluoroheptanoic acid (PFHpA) exposure to metabolic dysfunction associated steatotic liver disease in adolescents.Communications medicine · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention.International journal of molecular sciences · 2025Review
- Decoding the Liver-Heart Axis in Cardiometabolic Diseases.Circulation research · 2025Review
- Association of liver fibrosis-4 index with functional outcomes in chinese patients with acute ischemic stroke undergoing mechanical thrombectomy.Scientific reports · 2025Article
- Association Between Liver Fibrosis Markers and Hemorrhagic Transformation Following Endovascular Treatment for Acute Ischemic Stroke: A Chinese Stroke Center Study.International journal of general medicine · 2025Article
- Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review.Cardiovascular diabetology · 2024Review
- The Interplay between Liver Sinusoidal Endothelial Cells, Platelets, and Neutrophil Extracellular Traps in the Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of clinical medicine · 2024Review
- Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines.Life (Basel, Switzerland) · 2024Review
- Association of nonalcoholic fatty liver disease and venous thromboembolic disease in healthy adults in Korea: a nationwide study.Scientific reports · 2023Article
- Coagulation Dysfunctions in Non-Alcoholic Fatty Liver Disease-Oxidative Stress and Inflammation Relevance.Medicina (Kaunas, Lithuania) · 2023Review
- Association between fatty liver index and blood coagulation markers: a population-based study.Lipids in health and disease · 2023Article
- Oral Anticoagulation in Patients with Chronic Liver Disease.Medicina (Kaunas, Lithuania) · 2023Review
- Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist.Nutrients · 2023Review
- Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.World journal of gastroenterology · 2023Review
- Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications.Journal of clinical and translational hepatology · 2022Review
- "Liver-gut" axis: A target of traditional Chinese medicine for the treatment of non-alcoholic fatty liver disease.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is associated with a number of extrahepatic comorbidities and considerable cardiovascular morbidity and mortality, which is possibly related to coagulation changes associated with metabolic syndrome. Coagulation disorders are common in patients with liver disease of any etiology, and here we review possible alterations in coagulation cascade specific to NAFLD. We discuss derangements in the coagulation cascade and fibrinolysis, endothelial dysfunction, and platelet abnormalities as possible culprits for altered coagulation and explore the significance of these changes for potential treatment targets.
Indexed as
Identifiers
33660958PMC7976878W3135509072What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.